IP Library Granted Patent US 8,940,857
Granted Patent B2
US 8,940,857 · App. 12/870,989 · Granted Jan 27, 2015

Methods and compositions for enhancing delivery of double-stranded RNA or a double-stranded hybrid nucleic acid to regulate gene expression in mammalian cells

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,940,857
App. No.
12/870,989
Granted
Jan 27, 2015
Kind
B2
Abstract

A delivery-enhancing peptide comprising the amino acid sequence of SEQ ID NO:11 or salt thereof. This invention is directed towards methods and compositions to administer a double-stranded ribonucleic acid to a mammal so as to effectuate transfection of the double-stranded RNA into a desired tissue of the mammal.

Claims (9)

1. A delivery-enhancing peptide comprising the amino acid sequence of SEQ ID NO: 11 or salt thereof.

2. The delivery-enhancing peptide of claim 1 , wherein the delivery-enhancing peptide is modified by incorporation of one or more amino- and/or carboxy-terminal chemical modifications .

3. The delivery-enhancing peptide of claim 2 , wherein the one or more amino- and/or carboxy-terminal chemical modifications are selected from the group consisting of an amide, BrAc, and maleimide group.

4. A composition comprising a delivery-enhancing peptide comprising the amino acid sequence of SEQ ID NO: 11 or salt thereof, and a nucleic acid.

5. The composition of claim 4 , wherein the nucleic acid is a single stranded nucleic acid or a double-stranded nucleic acid.

6. The composition of claim 4 , wherein the nucleic acid comprises RNA and/or DNA.

7. The composition of claim 4 , wherein the nucleic acid is an siRNA or siHybrid.

8. The composition of claim 4 , wherein the delivery-enhancing peptide is in a complex with the nucleic acid or is conjugated to the nucleic acid.

9. The composition of claim 4 further comprising a surfactant, liposome, long chain amphipathic molecule, cyclodextrin , chelating agent, amino acid or salt thereof, or any combination thereof.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Apr 14, 2014
From: GENESIS CAPITAL MANAGEMENT, LLC, AS AGENT
To: MARINA BIOTECH, INC.; CEQUENT PHARMACEUTICALS, INC.; MDRNA RESEARCH, INC.
Reel/Frame 032685/0158 →
SECURITY AGREEMENT Recorded May 13, 2013
From: MARINA BIOTECH, INC.; CEQUENT PHARMACEUTICALS, INC.; MDRNA RESEARCH, INC.
To: MONSANTO COMPANY
Reel/Frame 030401/0461 →
CHANGE OF NAME Recorded Apr 28, 2012
From: MDRNA, INC.
To: MARINA BIOTECH, INC.
Reel/Frame 028124/0076 →
SECURITY AGREEMENT Recorded Feb 15, 2012
From: MARINA BIOTECH, INC; CEQUENT PHARMACEUTICALS, INC.; MDRNA RESEARCH, INC.
To: GENESIS CAPITAL MANAGEMENT, LLC, AS AGENT
Reel/Frame 027712/0200 →